Prelude Therapeutics (PRLD) Change in Cash (2019 - 2026)

Prelude Therapeutics has reported Change in Cash for 8 years, with the latest figure at -$13.5 million in Q1 2026.

• Quarterly Change in Cash fell 148.57% year-over-year to -$13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.3 million (down 224.16% YoY) and the FY2025 annual result came in at $22.0 million, up 271.44% from the prior year.
• Change in Cash fell to -$13.5 million in Q1 2026 per PRLD's latest filing, from -$12.3 million in the prior quarter.
• Over five years, Change in Cash peaked at $27.8 million in Q1 2025 and troughed at -$21.4 million in Q4 2022.
• A 5-year average of -$640058.8 and a median of -$584000.0 in 2024 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 4859.42% in 2025, down 1016.12% in 2025.
• Over 5 years, Change in Cash stood at -$21.4 million in 2022, then soared by 143.87% to $9.4 million in 2023, then sank by 85.74% to $1.3 million in 2024, then tumbled by 1016.12% to -$12.3 million in 2025, then fell by 9.97% to -$13.5 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$13.5 million, -$12.3 million, and $21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.